SPECIFIC OBJECTIVES

Primary objectives

To estimate and compare the immune-related adverse events (irAEs) incidence in female and male cancer patients treated with immunotherapy, and estimate the incidence according to different clinical features and gender dimensions , i.e. behavioral and psychosocial differences associated with being female or male.

To estimate and compare the irAEs incidence in pre- and postmenopausal women.

Secondary objectives

To develop irAEs predictive tools based on clinical characteristics.
To explore irAEs occurrence in relation to hormonal profiles, exploring the differences in female and male cancer patients, and in pre- vs post-menopausal female patients.
To explore the role of concomitant medications on irAEs occurrence.

Translational objectives

Gene-expression analysis: to identify immune-related genes in patients with various solid tumors treated with immunotherapy associated with the development of irAEs.
SNPs analysis: to perform a preliminary genome wide association study for the identification of germline variations associated with the development of irAEs. with the hypothesis that the individual’s genetic makeup may be related to irAEs.
Microbioma analysis: to analyze gut microbiota aiming at performing RNA/DNA sequencing analysis for identifying components associated with the development of irAEs.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 741874. More information on the http://gender-net-plus.eu/ The contents of this website and the view expressed in the news and publications are the sole responsibility of the authors and under no circumstances can be regarded as reflecting the position of the European Union.
Send us an email: g.definer19@gmail.com
Legal Notice / Cookie Policy.

Copyright © 2020 G-DEFINER | Powered by G-DEFINER
Graphics for this website have been provided by the G-DEFINER Consortium Partners. No part of this website may be used, Reproduced and/or disclosed in any form or by any means without the prior written permission of the G-DEFINER Consortium Partners